Bolt Biotherapeutics Inc.

2.02-0.1300-6.05%Vol 2.32M1Y Perf -86.60%
Jun 24th, 2022 16:00 DELAYED
BID1.98 ASK2.08
Open2.14 Previous Close2.15
Pre-Market- After-Market2.02
 - -  - -%
Target Price
8.67 
Analyst Rating
Moderate Buy 1.67
Potential %
329.21 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     55.65
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.52 
Earnings Rating
Market Cap75.69M 
Earnings Date
11th Aug 2022
Alpha-0.15 Standard Deviation0.28
Beta2.00 

Today's Price Range

1.932.15

52W Range

1.3919.29

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Neutral
Performance
1 Week
12.85%
1 Month
19.53%
3 Months
-28.87%
6 Months
-57.29%
1 Year
-86.60%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BOLT2.02-0.1300-6.05
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.71-0.649.86
Q04 2021-0.66-0.73-10.61
Q03 2021-0.63-0.630.00
Q02 2021-0.38-0.64-68.42
Q01 2021-0.64-0.86-34.38
Q04 2020-0.72-7.95-1 004.17
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.68
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.32M
Shares Outstanding37.47K
Shares Float25.04M
Trades Count3.74K
Dollar Volume4.70M
Avg. Volume372.95K
Avg. Weekly Volume549.09K
Avg. Monthly Volume302.62K
Avg. Quarterly Volume267.13K

Bolt Biotherapeutics Inc. (NASDAQ: BOLT) stock closed at 2.02 per share at the end of the most recent trading day (a -6.05% change compared to the prior day closing price) with a volume of 2.32M shares and market capitalization of 75.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 63 people. Bolt Biotherapeutics Inc. CEO is Randall C. Schatzman.

The one-year performance of Bolt Biotherapeutics Inc. stock is -86.6%, while year-to-date (YTD) performance is -58.78%. BOLT stock has a five-year performance of %. Its 52-week range is between 1.39 and 19.285, which gives BOLT stock a 52-week price range ratio of 3.52%

Bolt Biotherapeutics Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.29, a price-to-sale (PS) ratio of 32.36, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.19%, a ROC of -34.73% and a ROE of -38.01%. The company’s profit margin is -%, its EBITDA margin is -4 677.30%, and its revenue ttm is $2.07 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Bolt Biotherapeutics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. Bolt Biotherapeutics Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Bolt Biotherapeutics Inc. is Moderate Buy (1.67), with a target price of $8.67, which is +329.21% compared to the current price. The earnings rating for Bolt Biotherapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bolt Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bolt Biotherapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 40.41, ATR14 : 0.20, CCI20 : 60.57, Chaikin Money Flow : -0.01, MACD : 0.04, Money Flow Index : 46.10, ROC : -6.91, RSI : 54.90, STOCH (14,3) : 45.57, STOCH RSI : 0.58, UO : 53.53, Williams %R : -54.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bolt Biotherapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Moderate Buy
2.00

Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

CEO: Randall C. Schatzman

Telephone: +1 650 665-9295

Address: 900 Chesapeake Drive, Redwood 94063, CA, US

Number of employees: 63

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

58%42%

TipRanks News for BOLT

Sun, 01 May 2022 16:45 GMT Bolt Biotherapeutics (BOLT) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Sat, 02 Apr 2022 01:58 GMT Analysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Abeona Therapeutics (ABEO) and Reata Pharmaceuticals (RETA)

- TipRanks. All rights reserved.

Fri, 01 Apr 2022 13:07 GMT Bolt Biotherapeutics (BOLT) Gets a Buy Rating from JonesTrading

- TipRanks. All rights reserved.

News

Stocktwits